Impact of Circadian Exercise on Metabolic Dysfunction-Associated Steatotic Liver Disease in Postmenopausal Women
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Morning exercise group, Evening exercise group, Usual-care control group.
- Кому может быть актуально
- Состояния в реестре: Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Diseases, Exercise. Базовые параметры: 45 лет — 75 лет · Женщины.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Испания
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
Type of Study: Clinical Trial Goal: The goal of this clinical trial is to investigate how performing exercise at different times of day (morning vs. evening) affects liver fat, cardiometabolic health, and gut microbiota in postmenopausal women. Participant Population/Health Conditions: The study will involve 63 sedentary postmenopausal women (aged 45-75) diagnosed with metabolic dysfunction-associated steatotic liver disease. Main Questions: The main questions this study aims to answer are: * Does morning exercise reduce hepatic fat more effectively than evening exercise? * How does time-of-day-specific exercise influence cardiometabolic markers? * Do changes in gut microbiota contribute to the metabolic effects of exercise timing? Participants Will: Be randomized into one of three groups: morning exercise, evening exercise, or a usual-care control group. Follow the assigned regimen for 12 weeks. The exercise groups will perform supervised aerobic and resistance training three times per week. Provide blood, stool, and imaging data before and after the intervention to determine the effects of the intervention. Comparison Group: Researchers will compare the effects of morning vs. evening exercise (and usual care) on hepatic fat reduction and cardiometabolic improvement, as well as changes in gut microbiota.
Подробное описание
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one in three adults and is a major contributor to the growing burden of cardiometabolic disease. Exercise is one of the most effective interventions for improving cardiometabolic health, reducing hepatic fat, and enhancing metabolic flexibility. However, the timing of exercise -a modifiable behavioral factor- may play a crucial yet underexplored role in determining its physiological benefits.
Preclinical studies have shown that circadian rhythms regulate key metabolic processes, including lipid metabolism and glucose homeostasis. Moreover, recent findings suggest that exercise performed at different times of day may elicit different responses, influencing the regulation of hepatic fat and systemic inflammation. These effects may be mediated, in part, through gut microbiota, which modulate host metabolism via the gut-liver axis. However, the interaction between exercise timing and gut microbiota in human physiology -particularly in women- remains poorly understood.
This knowledge gap is particularly critical in postmenopausal women, a population that experiences profound metabolic changes due to hormonal decline, including increased hepatic and visceral fat, chronic inflammation, and reduced insulin sensitivity. These alterations significantly elevate the risk for MASLD and other cardiometabolic diseases. Yet, postmenopausal women are consistently underrepresented in clinical trials exploring exercise interventions.
Based on emerging scientific evidence, the investigators hypothesize that morning exercise may lead to greater reductions in hepatic fat and improvements in cardiometabolic health compared to evening exercise in postmenopausal women with MASLD. Furthermore, the investigators propose that these effects may be partially mediated by exercise-induced changes in gut microbiota composition and function.
Thus, the main objective of the project is to investigate whether the timing of exercise modulates hepatic fat reduction, cardiometabolic adaptation, and gut microbiota remodeling in postmenopausal women with MASLD. To achieve this, the project will implement a randomized controlled trial in which 63 sedentary postmenopausal women diagnosed with MASLD will be randomly allocated into one of three groups: (i) morning exercise (07:00h), (ii) evening exercise (19:00h), or (iii) a usual-care control group receiving lifestyle recommendations.
Participants in the intervention groups will complete a 12-week supervised training program, combining aerobic and resistance exercise (3 sessions/week, 60-90 minutes per session), in accordance with WHO recommendations. Before and after the intervention, biological samples, magnetic resonance imaging, and metabolic assessments will be collected. The study will employ advanced multi-omics analyses, including metabolomics and semi-targeted metagenomics, to explore how gut microbiota changes relate to improvements in metabolism.
Вмешательства
- Поведенческое Morning exercise group
Participants perform supervised exercise sessions at 07:00h - Поведенческое Evening exercise group
Participants perform supervised exercise sessions at 19:00h - Поведенческое Usual-care control group
Participants receive lifestyle recommendations without exercise
Первичные конечные точки
- Hepatic fat content [Срок оценки: Change from baseline in the mean adipose tissue content at 12 weeks]
Вторичные конечные точки (12)
- Visceral adipose tissue [Срок оценки: Change from baseline in the mean adipose tissue content at 12 weeks]
- Intra-muscular adipose tissue [Срок оценки: Change from baseline in the mean adipose tissue content at 12 weeks]
- Body composition [Срок оценки: Change from baseline in the whole-body composition at 12 weeks]
- Bone related parameters [Срок оценки: Change from baseline in the whole-body mineral density and content at 12 weeks]
- Resting blood pressure [Срок оценки: Change from baseline in the resting blood pressure related parameters at 12 weeks]
- Glucose metabolism [Срок оценки: Change from baseline in the glucose related parameters at 12 weeks]
- Energy metabolism [Срок оценки: Change from baseline in the energy metabolism related parameters at 12 weeks]
- Cardiorespiratory Fitness [Срок оценки: Change from baseline in the cardiorespiratory fitness at 12 weeks]
- Muscular strength [Срок оценки: Change from baseline in the muscular strength related parameters at 12 weeks]
- 30 seconds sit-to-stand test [Срок оценки: Change from baseline in the sit-to-stand related parameters at 12 weeks]
- Heart rate and heart rate variability [Срок оценки: Change from baseline in the heart rate and heart rate variability related parameters at 12 weeks]
- Body weight [Срок оценки: Change from baseline in the body weight at 12 weeks]
Критерии участия
Критерии включения
- Women aged 45-75 years, postmenopausal for at least two years (stage +1a)
- Body Mass Index (BMI) > 25 and < 40 kg/m²
- Diagnosed hepatic steatosis (via ultrasound hyperechogenicity, FibroScan CAP score >280, or histological confirmation)
- Sedentary lifestyle (no regular structured exercise)
- Willingness to be randomized and adhere to study procedures, including all assessments and visits
- Sufficient Spanish proficiency to understand and follow study instructions
- Consent to store biological samples for future research
- Participants should have a healthy circadian rhythm
Критерии исключения
- Contraindications for MRI (e.g., claustrophobia, pacemaker, metal implants)
- History of major cardiovascular, endocrine, neurological, or kidney disease, or any clinical abnormalities (to be judged by the study physician)
- First-degree family history of sudden cardiac death
- Alcohol or substance abuse
- Psychiatric, psychotic, eating, or sleep disorders (to be judged by the study physician)
- Prior bariatric surgery, diagnosed HIV/AIDS, or inflammatory/autoimmune diseases
- Cancer or any medical condition where exercise is contraindicated (to be judged by the study physician)
- Recent or unstable metabolic conditions (e.g., diabetes, recent medication changes, or use of drugs affecting metabolism)
- Recent (<3 months) use of antibiotics, statins, glucocorticoids, hormonal therapies, amiodarone, or myelosuppressive agents
- Participation in weight-loss programs or special diets (e.g., ketogenic, high-carb)
- Shift workers or caregivers with frequent nocturnal disruptions
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Лечение
Центры проведения
Испания · 1 центр
- Universidad de Almería — Almería
Идентификаторы
NCT: NCT07386665 · UALBIO2025/008